|
1
|
Nusse R: Wnt signaling in disease and in
development. Cell Res. 15:28–32. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DiMeo TA, Anderson K, Phadke P, Fan C,
Feng C, Perou CM, Naber S and Kuperwasser C: A novel lung
metastasis signature links Wnt signaling with cancer cell
self-renewal and epithelial-mesenchymal transition in basal-like
breast cancer. Cancer Res. 69:5364–5373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Komiya Y and Habas R: Wnt signal
transduction pathways. Organogenesis. 4:68–75. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drees F, Pokutta S, Yamada S, Nelson WJ
and Weis WI: Alpha-catenin is a molecular switch that binds
E-cadherin- beta-catenin and regulates actin-filament assembly.
Cell. 123:903–915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Micalizzi DS, Farabaugh SM and Ford HL:
Epithelial- mesenchymal transition in cancer: Parallels between
normal development and tumor progression. J Mammary Gland Biol
Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hardie DG, Ross FA and Hawley SA: AMPK: A
nutrient and energy sensor that maintains energy homeostasis. Nat
Rev Mol Cell Biol. 13:251–262. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patel VA, Massenburg D, Vujicic S, Feng L,
Tang M, Litbarg N, Antoni A, Rauch J, Lieberthal W and Levine JS:
Apoptotic cells activate AMP-activated protein kinase (AMPK) and
inhibit epithelial cell growth without change in intracellular
energy stores. J Biol Chem. 290:22352–22369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaw RJ: LKB1 and AMP-activated protein
kinase control of mTOR signalling and growth. Acta Physiol (Oxf).
196:65–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Corradetti MN, Inoki K, Bardeesy N,
DePinho RA and Guan KL: Regulation of the TSC pathway by LKB1:
Evidence of a molecular link between tuberous sclerosis complex and
Peutz-Jeghers syndrome. Genes Dev. 18:1533–1538. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zulato E, Bergamo F, De Paoli A, Griguolo
G, Esposito G, De Salvo GL, Mescoli C, Rugge M, Nardin M, Di Grazia
L, et al: Prognostic significance of AMPK activation in advanced
stage colorectal cancer treated with chemotherapy plus bevacizumab.
Br J Cancer. 111:25–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Madiraju AK, Erion DM, Rahimi Y, Zhang XM,
Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald
MJ, et al: Metformin suppresses gluconeogenesis by inhibiting
mitochondrial glycerophosphate dehydrogenase. Nature. 510:542–546.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Viollet B, Guigas B, Sanz Garcia N,
Leclerc J, Foretz M and Andreelli F: Cellular and molecular
mechanisms of metformin: An overview. Clin Sci (Lond). 122:253–270.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yue W, Yang CS, DiPaola RS and Tan XL:
Repurposing of metformin and aspirin by targeting AMPK-mTOR and
inflammation for pancreatic cancer prevention and treatment. Cancer
Prev Res (Phila). 7:388–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shang S, Hua F and Hu ZW: The regulation
of β-catenin activity and function in cancer: Therapeutic
opportunities. Oncotarget. 8:33972–33989. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cadigan KM and Waterman ML: TCF/LEFs and
Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol.
4(pii): a0079062012.PubMed/NCBI
|
|
17
|
Stamos JL and Weis WI: The β-catenin
destruction complex. Cold Spring Harb Perspect Biol. 5:a0078982013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fang D, Hawke D, Zheng Y, Xia Y,
Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T and Lu Z:
Phosphorylation of beta-catenin by AKT promotes beta-catenin
transcriptional activity. J Biol Chem. 282:11221–11229. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhan T, Rindtorff N and Boutros M: Wnt
signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park SY, Lee YK, Lee WS, Park OJ and Kim
YM: The involvement of AMPK/GSK3-beta signals in the control of
metastasis and proliferation in hepato-carcinoma cells treated with
anthocyanins extracted from Korea wild berry Meoru. BMC Complement
Altern Med. 14:1092014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Z, He X, Jia M, Liu Y, Qu D, Wu D, Wu
P, Ni C, Zhang Z, Ye J, et al: β-catenin overexpression in the
nucleus predicts progress disease and unfavourable survival in
colorectal cancer: A meta-analysis. PLoS One. 8:e638542013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kraus C, Liehr T, Hülsken J, Behrens J,
Birchmeier W, Grzeschik KH and Ballhausen WG: Localization of the
human beta-catenin gene (CTNNB1) to 3p21: A region implicated in
tumor development. Genomics. 23:272–274. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Motoshima H, Goldstein BJ, Igata M and
Araki E: AMPK and cell proliferation-AMPK as a therapeutic target
for atherosclerosis and cancer. J Physiol. 574:63–71. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li W, Saud SM, Young MR, Chen G and Hua B:
Targeting AMPK for cancer prevention and treatment. Oncotarget.
6:7365–7378. 2015.PubMed/NCBI
|
|
26
|
Luo Z, Zang M and Guo W: AMPK as a
metabolic tumor suppressor: Control of metabolism and cell growth.
Future Oncol. 6:457–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jang GB, Kim JY, Cho SD, Park KS, Jung JY,
Lee HY, Hong IS and Nam JS: Blockade of Wnt/β-catenin signaling
suppresses breast cancer metastasis by inhibiting CSC-like
phenotype. Sci Rep. 5:124652015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang H, Xue J, Li M, Zhao X, Wei D and Li
C: Metformin regulates stromal-epithelial cells communication via
Wnt2/β-catenin signaling in endometriosis. Mol Cell Endocrinol.
413:61–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Markowska A, Pawałowska M, Filas V, Korski
K, Gryboś M, Sajdak S, Olejek A, Bednarek W, Spiewankiewicz B,
Lubin J and Markowska J: Does metformin affect ER, PR, IGF-1R,
β-catenin and PAX-2 expression in women with diabetes mellitus and
endometrial cancer? Diabetol Metab Syndr. 5:762013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao J, Meng S, Chang E, Beckwith-Fickas K,
Xiong L, Cole RN, Radovick S, Wondisford FE and He L: Low
concentrations of metformin suppress glucose production in
hepatocytes through AMP-activated protein kinase (AMPK). J Biol
Chem. 289:20435–20446. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Erices R, Bravo ML, Gonzalez P, Oliva B,
Racordon D, Garrido M, Ibañez C, Kato S, Brañes J, Pizarro J, et
al: Metformin, at concentrations corresponding to the treatment of
diabetes, potentiates the cytotoxic effects of carboplatin in
cultures of ovarian cancer cells. Reprod Sci. 20:1433–1446. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chae YK, Arya A, Malecek MK, Shin DS,
Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L
and Giles F: Repurposing metformin for cancer treatment: Current
clinical studies. Oncotarget. 7:40767–40780. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ruiter R, Visser LE, van Herk-Sukel MP,
Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings
RM and Stricker BH: Lower risk of cancer in patients on metformin
in comparison with those on sulfonylurea derivatives: Results from
a large population-based follow-up study. Diabetes Care.
35:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van Staa TP, Patel D, Gallagher AM and de
Bruin ML: Glucose-lowering agents and the patterns of risk for
cancer: A study with the General Practice Research Database and
secondary care data. Diabetologia. 55:654–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Griss T, Vincent EE, Egnatchik R, Chen J,
Ma EH, Faubert B, Viollet B, DeBerardinis RJ and Jones RG:
Metformin antagonizes cancer cell proliferation by suppressing
mitochondrial-dependent biosynthesis. PLoS Biol. 13:e10023092015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li N, Ragheb K, Lawler G, Sturgis J, Rajwa
B, Melendez JA and Robinson JP: Mitochondrial complex I inhibitor
rotenone induces apoptosis through enhancing mitochondrial reactive
oxygen species production. J Biol Chem. 278:8516–8525. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sherwood V: WNT signaling: An emerging
mediator of cancer cell metabolism? Mol Cell Biol. 35:2–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shin JH, Kim HW, Rhyu IJ and Kee SH: Axin
is expressed in mitochondria and suppresses mitochondrial ATP
synthesis in HeLa cells. Exp Cell Res. 340:12–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
